DBV Technologies Stock (DBVT) Soars as Clinical Trial Results Trigger Analyst Price Target Increases

DBV Technologies (DBVT) stock underwent a massive rally on Wednesday after positive coverage from top analysts following a clinical trial update.

Let’s dig into the updated DBVT stock coverage investors need to know about below.

• Five-star Guggenheim analyst Yatin Suneja reiterated a Buy rating and increased his price target to $51 from $35, representing a potential 183.65% upside for the stock.
• Five-star LifeSci Capital analyst Sam Slutsky maintained a Buy rating and raised his price target to $48 from $19, implying a possible 166.96% upside for the shares.
• Five-star Citizens JMP analyst Jonathan Wolleben kept a Buy rating and boosted his price target to $45 from $21, suggesting a plausible 150.28% upside for the units.

The catalysts for the updated DBV Technologies analyst coverage today were the results from the Phase 3 VITESSE Trial of its VIASKIN Peanut Patch. The big news here was that the trial met its primary endpoint, as 46.6% of children in the trial met response criteria at 12 months, compared to 4.8% of children in the placebo arm.

DBV Technologies Stock Movement Today

DBV Technologies stock was up 32.59% in pre-market trading on Wednesday, following a 1.69% dip yesterday. The stock has also rallied 481.88% year-to-date and the same over the past 12 months.

With today’s news came heavy trading of DBVT stock, as some 758,000 shares changed hands. To put that in perspective, the company’s three-month daily average trading volume is about 329,000 units.

Is DBV Technologies Stock a Buy, Sell, or Hold?

Turning to Wall Street, the analysts’ consensus rating for DBV Technologies is Strong Buy, based on five Buy ratings over the past three months. With that comes an average DBVT stock price target of $44.20, representing a potential 145.83% upside for the shares.

See more DBVT stock analyst ratings